ALZpath's Proprietary pTau217 Antibody Featured in 86 Presentations at AAIC 2026

ALZpath, Inc. announced that its proprietary pTau217 antibody will be highlighted in 86 scientific presentations across Alzheimer’s research and diagnostics at the Alzheimer's Association International Conference (AAIC) 2026. The antibody has been adopted by major diagnostic firms including Abbott and Roche for developing assays.

By ALZpath, Inc. · PR Newswire · July 13, 2026, 08:27 UTC

Tickers: $ABT $ALMR $QTRX $SIEGY $TECH

Topics: Alzheimer's disease antibodies diagnostics scientific research

Read the full article at PR Newswire

More World news

Nvidia CEO Jensen Huang Resigns Amid Investigation and Personal Allegations Motley Fool · November 12, 2026, 17:20 UTC
Argus Research Upgrades Republic Services to Buy Seeking Alpha · November 12, 2026, 17:16 UTC
Moderna Shares Decline Following Analyst Day Projections and Future Cost Concerns Motley Fool · November 12, 2026, 17:13 UTC
United Airlines Restricts AI Agent Access to Booking Systems Due to Cybersecurity and Regulatory Concerns TechCrunch · November 12, 2026, 17:17 UTC
Global Payments Shares Drop 12% Following Reports Private Equity Firms Abandoned Takeover Bid Seeking Alpha · November 12, 2026, 17:14 UTC
Nvidia Appoints Colette Kress as Interim CEO Following Jensen Huang's Resignation CNBC · November 12, 2026, 16:59 UTC
Brookfield Corporation Reports Strong Third Quarter Earnings Growth and Increased Share Buybacks Motley Fool · November 12, 2026, 17:08 UTC
Franco-Nevada Reports Q3 2026 Revenue Growth Driven by Higher Gold and Oil Prices Motley Fool · November 12, 2026, 17:10 UTC
Stratasys Reports Q3 2026 Revenue Growth Driven by Aerospace and Defense Demand Motley Fool · November 12, 2026, 17:11 UTC
Jim Cramer Advises Profit-Taking Following Jensen Huang's Resignation at Nvidia CNBC · November 12, 2026, 16:59 UTC